American Association for Cancer Research® (AACR) annual meeting is the largest cancer research conference in the world. The 2024 AACR annual meeting will be held in San Diego, USA, from April 5th to 10th to share the latest advancements in cancer and related biomedical sciences. Nanjing Leads Biolab

American Association for Cancer Research® (AACR) annual meeting 2024 will be held in San Diego, USA from April 5 to 10, 2024, EST. Renowned as one of the largest academic events in cancer research, AACR annual meeting attracts tens of thousands of professionals from all over the world every year, di

The annual meeting of the American Society of Hematology (ASH) is the largest and most comprehensive international academic event in the field of hematology in the world. The 65th annual meeting of ASH will be held in San Diego, USA from December 9 to 12, 2023. Nanjing Leads Biolabs (Leads Biolabs)

The Annual Meeting of Society for Immunotherapy of Cancer (SITC) is the largest international event focusing on cancer immunotherapy in the world, attracting more than 3,500 participants each year from academia, regulatory authorities and government agencies. At this year's SITC Annual Meeting, whic

NANJING, China, July 31, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") announced today that the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) have approved its first-in-human Investigational New Drug (

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

NANJING, China, June 1, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the latest updated clinical data on the safety and efficacy of its anti-LAG-3 (lymphocyte activating gene-3) antibody LBL-007 and toripalimab combination therap

NANJING, China, April 27, 2023--Nanjing Leads Biolabs Co.，Ltd. (hereinafter referred to as "Leads Biolabs" or "Company") today announces that the first participant has been successfully dosed in a Phase Ⅰ/Ⅱ, first in human, multicenter, open-labeled, dose escalation and expansion study of LBL-033, a